Skip to main content
. Author manuscript; available in PMC: 2022 Sep 28.
Published in final edited form as: J Neurooncol. 2010 Jun 6;101(2):257–265. doi: 10.1007/s11060-010-0252-3

Table 4.

Overall response (OR) rates and overall survival (OS) achieved in HIV negative and positive patients according to the treatment modalities used

Treatment n OR P Median OS ± SE (mos) P
WBRT only
  HIV− 11   6 NS 10.3 ± 4.5
  HIV+   2   0 Not calculated
Chemotherapy only
  HIV−   7   4 NS 21.3 ± 8.5 NS
  HIV+ 16   9 4.0 ± 4.3
WBRT + chemotherapy
  HIV− 20 14 NS 23.8 ± 9.7 0.001
  HIV+   9   5 3.4 ± 1.5
No treatment
  HIV−   7 1.0 ± 10.9 NS
  HIV+ 14 0.7 ± 0.3

HIV− N = 45; HIV+ N = 41

SE standard error, WBRT whole brain radiotherapy

Chemotherapy regimens used: DeAngelis protocol, fludarabine + cytarabine, high dose methotrexate with or without temozolomide, Azidothymidine in combination with hydroxyurea or high dose methotrexate or high dose IL-2 + ganciclovir